Making Insulin Affordable for All Children Act
Latest Action
Referred to the Subcommittee on Work and Welfare.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Making Insulin Affordable for All Children Act (H.R. 1587) is a legislative proposal introduced in the 118th Congress aimed at addressing the affordability of insulin for children. The bill was referred to the Subcommittee on Work and Welfare on December 17, 2024, but it ultimately failed or expired without further action. Specific provisions, full text, and detailed summary of the bill are not available in the provided data, limiting detailed analysis of its content and mechanisms.
H.R. 1587 sought to make insulin more affordable for children but did not advance beyond subcommittee referral and expired without enactment.
- The bill focuses on insulin affordability specifically targeting children.
- It was introduced in the House of Representatives during the 118th Congress.
- The bill was referred to the Subcommittee on Work and Welfare but did not progress further.
['Children requiring insulin for diabetes management', 'Families of children with diabetes who face insulin affordability challenges', 'Healthcare providers and organizations focused on pediatric diabetes care']
['Lack of publicly available full text limits understanding of implementation details and funding mechanisms.', 'Potential cost implications for government healthcare programs or insurers are unknown.', 'Oversight and enforcement provisions cannot be assessed due to missing bill text.']
The bill was introduced in the 118th Congress and referred to a relevant subcommittee but did not advance, indicating limited legislative momentum. The focus on insulin affordability aligns with ongoing public health discussions about the cost of essential medications for chronic conditions like diabetes.
Hidden impact flags detected: 1
GovScope reviewed 1 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the bill could influence insulin pricing policies and insurance coverage for pediatric patients.', 'Potential reduction in financial barriers may improve health outcomes for children with diabetes.', 'Changes in insulin affordability could impact pharmaceutical market dynamics and healthcare spending.']
The absence of the full bill text and official summary restricts transparency and limits the ability to evaluate the bill's specific provisions, funding sources, and enforcement mechanisms. This lack of information poses challenges for public oversight and informed legislative debate.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.